The new spleen stiffness measurement (SSM by VCTE™) and the embedded ultrasound localization system enable risk stratification of patients with advanced chronic liver disease and portal hypertension.
 

SSM by VCTE™ is unique, patented and validated for portal hypertension assessment4. It is a new marker for non-invasive evaluation of spleen stiffness. 109 peer-reviewed publications support the use of SSM by VCTE™.

LSM by VCTE™ is unique, patented and validated for liver fibrosis assessment. It is the standard for non-invasive evaluation of liver stiffness1 with 3,245 international peer-reviewed publications.

CAP™ is unique patented and validated for liver steatosis assessment2,3 with 822 international peer-reviewed publications.
*CAP™ is available as an option.